One more research paper hot off the press:
https://journals.lww.com/annalsofsurgery/fulltext/2024/09000/benefits_of_aerosolized,_point_of_care,_autologous.11.aspxObjective:
To determine the utility of Autologous Skin Cell Suspension (ASCS) in closing full-thickness (FT) defects from injury and infection.Background:
Although ASCS has documented success in closing partial-thickness burns, far less is known about the efficacy of ASCS in FT defects.
Methods:
Fifty consecutive patients with FT defects (burn 17, necrotizing infection 13, crush 7, degloving 5, and other 8) underwent closure with the bilayer technique of 3:1 widely meshed, thin, split-thickness skin graft and 80:1 expanded ASCS. End points were limb salvage rate, donor site reduction, operative and hospital throughput, incidence of complications, and re-epithelialization by 4, 8, and 12 weeks.
Results:Definitive wound closure was achieved in 76%, 94%, and 98% of patients, at 4, 8, and 12 weeks, respectively. Limb salvage occurred in 42/43 patients (10 upper and 33 lower extremities). The mean area grafted was 435 cm2; donor site size was 212 cm2, representing a potential reduction of 50%. The mean surgical time was 71 minutes; the total operating room time was 124 minutes. The mean length of stay was 26.4 days; the time from grafting to discharge was 11.2 days. Four out of 50 patients (8%) required 6 reoperations for bleeding (1), breakdown (4), and amputation (1). Four out of 50 patients (8%) developed hypertrophic scarring, which responded to silicone sheeting (2) and laser resurfacing (2). The mean follow-up was 92.7 days.
Conclusions:
When used for the closure of FT wounds, point-of-care ASCS is effective and safe. Benefits include rapid re-epithelialization, high rate of limb salvage, reduction of donor site size and morbidity, and low incidence of hypertrophic scarring.
Ref: Papers of the 144th ASA Annual MeetingBenefits of Aerosolized, Point-of-care, Autologous Skin Cell Suspension (ASCS) for the Closure of Full-thickness Wounds From Thermal and Nonthermal CausesLearning Curves From the First 50 Consecutive Cases at an Urban, Level 1 Trauma CenterHultman, C. Scott MD, MBA*; Adams, Ursula C. MD, MBA†; Rogers, Corianne D. MD*; Pillai, Minakshi MS†; Brown, Samantha T. PA-C*; McGroarty, Carrie Ann PA-C*; McMoon, Michelle PA-C, PhD*; Uberti, M. Georgina MD‡Author InformationAnnals of Surgery 280(3) 452-462, September 2024. | DOI: 10.1097/SLA.0000000000006387
- Forums
- ASX - By Stock
- AVH
- RECELL Clinical Education (Warning: Graphic Medical Images)
RECELL Clinical Education (Warning: Graphic Medical Images), page-60
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVH (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.50 |
Change
-0.150(4.11%) |
Mkt cap ! $244.5M |
Open | High | Low | Value | Volume |
$3.79 | $3.85 | $3.32 | $3.375M | 944.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $3.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.53 | 19524 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 3.500 |
1 | 1700 | 3.470 |
1 | 3000 | 3.350 |
1 | 1000 | 3.330 |
1 | 395 | 3.320 |
Price($) | Vol. | No. |
---|---|---|
3.600 | 2594 | 3 |
3.700 | 2850 | 2 |
3.740 | 660 | 1 |
3.750 | 4392 | 2 |
3.790 | 1000 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
AVH (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online